Comparative Pharmacology
Head-to-head clinical analysis: OZOBAX versus RYANODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZOBAX versus RYANODEX.
OZOBAX vs RYANODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
Ryanodine receptor agonist; stabilizes the ryanodine receptor (RyR1) channel in skeletal muscle, reducing calcium leakage and improving excitation-contraction coupling.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
Dantrolene sodium: 2.5 mg/kg IV bolus, repeated as needed up to a cumulative dose of 10 mg/kg, then 1 mg/kg IV every 6 hours for 24-48 hours following malignant hyperthermia crisis.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Terminal elimination half-life is approximately 1.5-2 hours in healthy adults; prolonged in patients with hepatic impairment.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites accounts for the majority of elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant